Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas

Supplementary Tables S1-S5 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas

<p>Supplementary Tables S1-S5</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Karolin Heinze (16540724) (author)
Rannpháirtithe:	Evan S. Cairns (15025116) (author), Shelby Thornton (16540727) (author), Bronwyn Harris (16540730) (author), Katy Milne (16540733) (author), Marcel Grube (15048384) (author), Charlotte Meyer (16540736) (author), Anthony N. Karnezis (16540739) (author), Sian Fereday (15062070) (author), Dale W. Garsed (15013989) (author), Samuel C.Y. Leung (16540742) (author), Derek S. Chiu (15048474) (author), Malak Moubarak (16540745) (author), Philipp Harter (16540748) (author), Florian Heitz (15025143) (author), Jessica N. McAlpine (15025155) (author), Anna DeFazio (14952738) (author), David D.L. Bowtell (15048513) (author), Ellen L. Goode (15052532) (author), Malcolm Pike (16540751) (author), Susan J. Ramus (14932688) (author), C. Leigh Pearce (16540754) (author), Annette Staebler (15048714) (author), Martin Köbel (15013986) (author), Stefan Kommoss (15048360) (author), Aline Talhouk (11793988) (author), Brad H. Nelson (15019440) (author), Michael S. Anglesio (15025164) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Tumor Biology Epidemiology Genetics of Cancer Risk & Outcome Gynecological Cancers Ovarian cancer Tumor Microenvironment
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
de réir: Karolin Heinze (16540724)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 1 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
de réir: Sammy Ferri-Borgogno (15307295)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 2 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
de réir: Sammy Ferri-Borgogno (15307295)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 3 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
de réir: Sammy Ferri-Borgogno (15307295)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 4 from Spatial Transcriptomics Depict Ligand–Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors
de réir: Sammy Ferri-Borgogno (15307295)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
de réir: Kankan Cao (16437263)
Foilsithe / Cruthaithe: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
de réir: Cheng-Kai Wang (14963880)
Foilsithe / Cruthaithe: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
de réir: Daniel S. Green (15047598)
Foilsithe / Cruthaithe: (2025)

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
de réir: Yeh Wang (14964041)
Foilsithe / Cruthaithe: (2025)

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
de réir: Yeh Wang (14964041)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
de réir: Nicola S. Meagher (15048462)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
de réir: Nicola S. Meagher (15048462)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
de réir: Nicola S. Meagher (15048462)
Foilsithe / Cruthaithe: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
de réir: Nicola S. Meagher (15048462)
Foilsithe / Cruthaithe: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
de réir: Nicola S. Meagher (15048462)
Foilsithe / Cruthaithe: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
de réir: Nicola S. Meagher (15048462)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
de réir: Stephanie Lheureux (16797697)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
de réir: Stephanie Lheureux (16797697)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
de réir: Stephanie Lheureux (16797697)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
de réir: Stephanie Lheureux (16797697)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
de réir: Stephanie Lheureux (16797697)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
de réir: Nicola S. Meagher (15048462)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
de réir: Stephanie L. Wethington (16354020)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
de réir: Félix Blanc-Durand (15049400)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
de réir: Gwo Yaw Ho (14961416)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
de réir: Raphaël Leman (17314506)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
de réir: Raphaël Leman (17314506)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
de réir: Raphaël Leman (17314506)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
de réir: Raphaël Leman (17314506)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
de réir: Raphaël Leman (17314506)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
de réir: Raphaël Leman (17314506)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_t6cr2bna5afpj5jee92gbhaijs